AstraZeneca Beats Profit Estimate, Posts $15.38 Billion in Revenue on Cancer Drug Sales
businesscompany-earnings 3 posts · 3 accounts
AstraZeneca reported second-quarter core earnings that beat analyst expectations, driven by strong sales of blockbuster cancer treatments. The company posted earnings of $2.63 per share, surpassing the $2.48 estimate, on revenue of $15.38 billion.
The results reflect sustained strength in the company’s oncology portfolio, which drove the quarterly beat. The 18% year-over-year increase in core earnings underscores the commercial success of the cancer medicines, with revenue expanding 5% on a constant-currency basis.
From the sources (3 posts)
@wsjbusinessAstraZeneca Posts Sales Growth on Oncology Strength
@businessAstraZeneca reports higher-than-expected profit, buoyed by blockbuster cancer medicines
@theprintdeskASTRAZENECA Q2 CORE EPS $2.63 (+18% YOY); REVENUE $15.38B (+5% CC) VS $2.48 EPS ESTIMATE